TCTMD

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

WASHINGTON, DC—Two-year results from the ABSORB III study presented today at the American College of Cardiology 2017 Scientific Session show that the Absorb GT1 bioresorbable vascular scaffold (BVS, ...
Medscape

Negative Data Piling Up on Absorb Bioresorbable Scaffold

AMSTERDAM, NL — Consistent with prior trials, the risk of scaffold thrombosis was significantly higher in patients receiving the Absorb (Abbott Vascular) bioresorbable vascular scaffold (BVS) than an ...
Healio

ABSORB II: Bioresorbable scaffold outcomes comparable to DES at 1 year

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio WASHINGTON — The Absorb bioresorbable ...
Medscape

ABSORB-3 at 2 Years: More CV Events With Absorb BVS vs Xience

WASHINGTON, DC — Patients who received the Absorb (Abbott Vascular) bioresorbable vascular scaffold (BVS) in the ABSORB-3 trial showed a primary outcome, counting only events occurring between the ...
TCTMD

‘Worrisome’ 3-Year Data From ABSORB II Raise Concerns About First-Generation Bioresorbable Stent

WASHINGTON, DC—Three-year outcomes from the ABSORB II trial, a time point in which the Absorb GT1 bioresorbable vascular scaffold should be degraded, did not result in an improvement in vasomotor tone ...